Bio-Rad Laboratories, Inc. (BIO) News

Bio-Rad Laboratories, Inc. (BIO): $538.69

16.23 (+3.11%)

POWR Rating

Component Grades













Filter BIO News Items

BIO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BIO News Highlights

  • For BIO, its 30 day story count is now at 27.
  • Over the past 15 days, the trend for BIO's stories per day has been choppy and unclear. It has oscillated between 1 and 6.
  • RAD, AMN and BAX are the most mentioned tickers in articles about BIO.

Latest BIO News From Around the Web

Below are the latest news stories about Bio-Rad Laboratories Inc that investors may wish to consider to help them evaluate BIO as an investment opportunity.

Bio-Rad Laboratories Up 7% After Investor Day | February 25, 2022

Bio-Rad Presents Growth Strategy and Acceleration of Financial Targets at Investor Day

HERCULES, Calif., February 25, 2022--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, is hosting an in-person investor day beginning at 10:30 a.m. EST today in New York City. During the event, members of Bio-Rad’s executive leadership team will provide an in-depth overview of the Company’s growth strategy and new long-term financial targets, as well a closer look at the drivers within the two core business segments – Life

Yahoo | February 25, 2022

Myriad Genetics (MYGN) Reports Loss in Q4, Gross Margin Improves

Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has drove Q4 sales despite a challenging business environment.

Yahoo | February 25, 2022

Here's How Much You'd Have If You Invested $1000 in Bio-Rad Laboratories a Decade Ago

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Yahoo | February 25, 2022

Integra's (IART) Q4 Earnings Top Estimates, Gross Margin Drops

Integra (IART) records strong recovery in order demand in Q4 on broad-based strength in Neurosurgery and sales from the company's new CereLink ICP monitoring.

Yahoo | February 24, 2022

Insulet (PODD) Q4 Earnings Surpass Estimates, Margins Up

Insulet's (PODD) fourth-quarter 2021 revenues improved year over year on a strong performance of Omnipod, both in U.S. and international markets.

Yahoo | February 24, 2022

NuVasive (NUVA) Q4 Earnings Miss Estimates, Gross Margin Up

Continued strong international performance and introduction of products drove NuVasive's (NUVA) revenues in the fourth quarter of 2021.

Yahoo | February 24, 2022

Cerner (CERN) Q4 Earnings Surpass Estimates, Revenues Miss

Cerner's (CERN) fourth-quarter results benefit from gains across four of its business units.

Yahoo | February 24, 2022

LHC Group (LHCG) Q4 Earnings Miss Estimates, Revenues Beat

Despite the weak bottom-line performance, LHC Group's (LHCG) fourth-quarter results benefit from organic growth in home health admissions.

Yahoo | February 24, 2022

Fresenius Medical (FMS) Q4 Earnings Beat Estimates, Up Y/Y

Fresenius Medical's (FMS) fourth-quarter earnings benefit from strong performance across all the geographic regions and segments.

Yahoo | February 23, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5242 seconds.